Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q14722
UPID:
KCAB1_HUMAN
Alternative names:
K(+) channel subunit beta-1; Kv-beta-1
Alternative UPACC:
Q14722; A8K9H8; A8KAD4; B3KPZ4; Q13031; Q13302; Q16547; Q6PI60; Q99869
Background:
Voltage-gated potassium channel subunit beta-1, also known as Kv-beta-1, plays a crucial role in modulating the characteristics of channel-forming alpha-subunits, impacting action potentials and channel activity. It promotes the expression of alpha subunits at the cell membrane, enhancing channel activity. Kv-beta-1 is instrumental in the closure of delayed rectifier potassium channels and accelerates the closure of channels like KCNA1, KCNA2, and KCNA5. Additionally, it possesses NADPH-dependent aldoketoreductase activity, essential for down-regulating potassium channel activity.
Therapeutic significance:
Understanding the role of Voltage-gated potassium channel subunit beta-1 could open doors to potential therapeutic strategies.